Monday, August 14, 2017 1:58:39 PM
ARLZ... a $1 stock that has a product and some think company is worth $6 a share...
I have a 1/3 position to start...and want all the price swings this stock can muster before it's next earnings report... a 50% gain should be obtainable before the next earnings report; in fact in some ways it looks easy but Market volatility has had an impact...
Zontivity® look promising, and the company’s focus on high-risk patients for peripheral artery disease (PAD)...
Peripheral artery disease symptoms include:
Painful cramping in your hip, thigh or calf muscles after certain activities, such as walking or climbing stairs (claudication)
Leg numbness or weakness
Coldness in your lower leg or foot, especially when compared with the other side
Sores on your toes, feet or legs that won't heal
A change in the color of your legs
Hair loss or slower hair growth on your feet and legs
Slower growth of your toenails
Shiny skin on your legs
No pulse or a weak pulse in your legs or feet
Erectile dysfunction in men
If peripheral artery disease progresses, pain may even occur when you're at rest or when you're lying down (ischemic rest pain). It may be intense enough to disrupt sleep. Hanging your legs over the edge of your bed or walking around your room may temporarily relieve the pain.If your peripheral artery disease is caused by a buildup of plaques in your blood vessels (atherosclerosis), you're also at risk of developing:
Complications
Critical limb ischemia. This condition begins as open sores that don't heal, an injury, or an infection of your feet or legs. Critical limb ischemia occurs when such injuries or infections progress and can cause tissue death (gangrene), sometimes requiring amputation of the affected limb.
Stroke and heart attack. The atherosclerosis that causes the signs and symptoms of peripheral artery disease isn't limited to your legs. Fat deposits also build up in arteries supplying your heart and brain.
ARLZ (T/5-6) Aralez Pharmaceuticals June 7, 2017, Aralez announced the national commercial launch of Zontivity® in the U.S. The company had previously commenced a phased launch of Zontivity® in late April 2017 with 15 sales representatives targeting high volume physicians who treat post-myocardial infarction and peripheral artery disease (PAD) patients. .. Following a very rough first half of 2017 for Aralez, it appears as though the company has at least stabilized, and may be in the process of heading in the right direction. The early numbers for Zontivity® look promising, and the company’s focus on high-risk PAD patients may end up paying dividends. While YOSPRALA® is unlikely to ever live up to its original billing, its nice to see patients and prescribers responding favorably to the new pricing strategy. We will continue with updates on sales for Zontivity® and YOSPRALA® throughout the year, and are cautiously optimistic this may be the beginning of a turn around for the company. Our valuation remains $6.00, and now may be a good time for those with a high-risk tolerance to consider an investment in Aralez.
https://finance.yahoo.com/news/arlz-looking-capitalize-successful-launch-190000407.html
60minute
Daily
ARLZ
I have a 1/3 position to start...and want all the price swings this stock can muster before it's next earnings report... a 50% gain should be obtainable before the next earnings report; in fact in some ways it looks easy but Market volatility has had an impact...
Zontivity® look promising, and the company’s focus on high-risk patients for peripheral artery disease (PAD)...
Peripheral artery disease symptoms include:
Painful cramping in your hip, thigh or calf muscles after certain activities, such as walking or climbing stairs (claudication)
Leg numbness or weakness
Coldness in your lower leg or foot, especially when compared with the other side
Sores on your toes, feet or legs that won't heal
A change in the color of your legs
Hair loss or slower hair growth on your feet and legs
Slower growth of your toenails
Shiny skin on your legs
No pulse or a weak pulse in your legs or feet
Erectile dysfunction in men
If peripheral artery disease progresses, pain may even occur when you're at rest or when you're lying down (ischemic rest pain). It may be intense enough to disrupt sleep. Hanging your legs over the edge of your bed or walking around your room may temporarily relieve the pain.If your peripheral artery disease is caused by a buildup of plaques in your blood vessels (atherosclerosis), you're also at risk of developing:
Complications
Critical limb ischemia. This condition begins as open sores that don't heal, an injury, or an infection of your feet or legs. Critical limb ischemia occurs when such injuries or infections progress and can cause tissue death (gangrene), sometimes requiring amputation of the affected limb.
Stroke and heart attack. The atherosclerosis that causes the signs and symptoms of peripheral artery disease isn't limited to your legs. Fat deposits also build up in arteries supplying your heart and brain.
ARLZ (T/5-6) Aralez Pharmaceuticals June 7, 2017, Aralez announced the national commercial launch of Zontivity® in the U.S. The company had previously commenced a phased launch of Zontivity® in late April 2017 with 15 sales representatives targeting high volume physicians who treat post-myocardial infarction and peripheral artery disease (PAD) patients. .. Following a very rough first half of 2017 for Aralez, it appears as though the company has at least stabilized, and may be in the process of heading in the right direction. The early numbers for Zontivity® look promising, and the company’s focus on high-risk PAD patients may end up paying dividends. While YOSPRALA® is unlikely to ever live up to its original billing, its nice to see patients and prescribers responding favorably to the new pricing strategy. We will continue with updates on sales for Zontivity® and YOSPRALA® throughout the year, and are cautiously optimistic this may be the beginning of a turn around for the company. Our valuation remains $6.00, and now may be a good time for those with a high-risk tolerance to consider an investment in Aralez.
https://finance.yahoo.com/news/arlz-looking-capitalize-successful-launch-190000407.html
60minute
Daily
ARLZ
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
